Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/02/2874036/0/en/Arvinas-to-Present-at-Upcoming-Investor-Conferences.html
https://www.globenewswire.com/news-release/2024/04/24/2869136/0/en/Arvinas-Appoints-Randy-Teel-Ph-D-as-Chief-Business-Officer.html
https://www.fiercebiotech.com/biotech/novartis-pays-150m-arvinas-phase-3-ready-prostate-cancer-protein-degrader
https://www.globenewswire.com/news-release/2024/04/11/2861380/0/en/Arvinas-Enters-into-a-Transaction-with-Novartis-including-a-Global-License-Agreement-for-the-Development-and-Commercialization-of-PROTAC-Androgen-Receptor-AR-Protein-Degrader-ARV-7.html
https://www.globenewswire.com/news-release/2024/03/18/2848193/0/en/Arvinas-Appoints-Noah-Berkowitz-M-D-Ph-D-as-Chief-Medical-Officer.html
https://www.globenewswire.com//news-release/2024/03/04/2839389/0/en/Arvinas-to-Participate-in-Upcoming-Investor-Conferences.html
https://www.globenewswire.com//news-release/2024/02/27/2835846/0/en/Arvinas-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com//news-release/2024/02/20/2832286/0/en/Arvinas-Announces-Chief-Financial-Officer-Transition.html
https://www.globenewswire.com//news-release/2024/02/20/2831684/0/en/Arvinas-Announces-First-in-Human-Dosing-of-ARV-102-an-Investigational-PROTAC-Protein-Degrader-for-Neurodegenerative-Disease.html
https://www.globenewswire.com//news-release/2024/02/06/2824113/0/en/Arvinas-and-Pfizer-s-Vepdegestrant-ARV-471-Receives-FDA-Fast-Track-Designation-for-the-Treatment-of-Patients-with-ER-HER2-Metastatic-Breast-Cancer.html